OBJECTIVES: To examine whether antidepressant drugs are superior to placebo in the treatment of juvenile depression. METHOD: Extensive literature search was done to retrieve all randomised controlled and all uncontrolled trials describing children and adolescents with a diagnosis of depression who underwent any antidepressant drug treatment. In order to combine results, separate analyses using random effect models were conducted first for controlled and then for both controlled and open studies. RESULTS: 18 controlled and 23 open trials were submitted to meta-analysis. Tricyclics showed no significant benefit over placebo. Odds ratios for SSRIs were 1.84 (95% CI 1.35-2.50) for controlled and 1.83 (95% CI 1.40-2.40) for controlled and uncontrolled studies suggesting a significant benefit over placebo. Combining all antidepressants also gave confidence interval excluding the value one. CONCLUSIONS: Despite some promising data concerning the use of SSRIs in the treatment of adolescent depression, caution is warranted until the long-term safety of these agents can be demonstrated. Insufficient data are available to judge even the short term merits of these agents in prepubertal children. There is no evidence to support the use of tricyclics in this population.
OBJECTIVES: To examine whether antidepressant drugs are superior to placebo in the treatment of juvenile depression. METHOD: Extensive literature search was done to retrieve all randomised controlled and all uncontrolled trials describing children and adolescents with a diagnosis of depression who underwent any antidepressant drug treatment. In order to combine results, separate analyses using random effect models were conducted first for controlled and then for both controlled and open studies. RESULTS: 18 controlled and 23 open trials were submitted to meta-analysis. Tricyclics showed no significant benefit over placebo. Odds ratios for SSRIs were 1.84 (95% CI 1.35-2.50) for controlled and 1.83 (95% CI 1.40-2.40) for controlled and uncontrolled studies suggesting a significant benefit over placebo. Combining all antidepressants also gave confidence interval excluding the value one. CONCLUSIONS: Despite some promising data concerning the use of SSRIs in the treatment of adolescent depression, caution is warranted until the long-term safety of these agents can be demonstrated. Insufficient data are available to judge even the short term merits of these agents in prepubertal children. There is no evidence to support the use of tricyclics in this population.
Authors: Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Karen Soeken; Myde Boles; Frances Lynch Journal: Pediatrics Date: 2002-05 Impact factor: 7.124
Authors: A Apter; G Ratzoni; R A King; A Weizman; I Iancu; M Binder; M A Riddle Journal: J Am Acad Child Adolesc Psychiatry Date: 1994 Mar-Apr Impact factor: 8.829
Authors: B Geller; T B Cooper; D L Graham; H H Fetner; F A Marsteller; J M Wells Journal: J Am Acad Child Adolesc Psychiatry Date: 1992-01 Impact factor: 8.829
Authors: Xinyu Zhou; Bin Qin; Craig Whittington; David Cohen; Yiyun Liu; Cinzia Del Giovane; Kurt D Michael; Yuqing Zhang; Peng Xie Journal: BMJ Open Date: 2015-09-09 Impact factor: 2.692
Authors: Barry Wright; Lucy Tindall; Elizabeth Littlewood; Joy Adamson; Victoria Allgar; Sophie Bennett; Simon Gilbody; Chrissie Verduyn; Ben Alderson-Day; Lisa Dyson; Dominic Trépel; Shehzad Ali Journal: BMJ Open Date: 2014-10-31 Impact factor: 2.692